November 17th, 2026US loses measles elimination status; CDC outlines re-elimination planThe US lost measles elimination status after 26 years; CDC and partners plan to regain it via MMR vaccination and $100M in health department funding.Read more
November 16th, 2026Tirzepatide cuts BMI 18.5% in adolescents with obesityIn SURMOUNT-ADOLESCENTS, tirzepatide cut BMI 18.5% at 72 weeks vs a 0.5% rise with placebo in adolescents with obesity.Read more
November 16th, 2026Roflumilast cream 0.05% eases itch, improves QOL in infants with ADCaregivers reported itch, symptom, and QOL gains with roflumilast cream 0.05% in infants with AD; an FDA decision is due February 2027.Read more
November 16th, 2026Etavopivat for sickle cell disease submitted to FDA and EMANovo Nordisk filed etavopivat for SCD in patients aged 12+, backed by phase 3 HIBISCUS data showing a 27% drop in vaso-occlusive crises vs placebo.Read more
November 16th, 2026Semaglutide cuts BMI 13.5% in children aged 6 to 11 with obesityIn STEP Young, semaglutide cut BMI 13.5% at 68 weeks vs a 2.7% rise with placebo in children aged 6 to <12 years with obesity.Read more
November 13th, 2026Dupilumab for early EoE linked to lower asthma risk in young childrenIn a matched cohort of children aged 6 and younger with EoE, dupilumab was linked to less incident asthma than swallowed budesonide (10.5% vs 16.2%).Read more
November 12th, 2026Risankizumab shows 52-week efficacy in pediatric psoriasis trialFull OptIMMize-1 results show high skin clearance rates with risankizumab in children and teens with psoriasis, sustained through 52 weeks.Read more
November 10th, 2026Cariprazine improves mania and depression in pediatric bipolar IPost hoc data show cariprazine improved both manic and depressive symptoms through 52 weeks in youth aged 10 to 17 years with bipolar I disorder.Read more